Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2004

View Archived Issues

Avanir provides second quarter development highlights

PD-200437 prevents the development of osteoarthritis in vivo

Potent in vivo antinociceptive effects of orally active agent by Mochida

Weight loss and appetite reduction found with Axokine in overweight/obese subjects

ATL-962 reported to reduce body weight of obese patients

Lundbeck highlights recent developments

Pharmacokinetics of vBAFF-R:Fc in healthy mice and a mouse model of arthritis

OGX-O11 potently inhibits clusterin expression in prostate cancer

First randomized trial to confirm Her1/EGFR inhibitor prolongs survival in NSCLC after chemotherapy

Novel orally active antiinflammatory adhesion molecule inhibitor

Quarterly progress at Cytokinetics

MP-1 changes name to Phoenix Biosciences

Wyeth and Karo Bio extend collaboration, advance lead compound

Phase II data supports progression of Onyvax-P for advanced prostate cancer

PRDT's ligand technology binds and removes viruses from blood product

Prosidion to acquire DPP-IV platform from Probiodrug

IPL-512602 fails to meet primary endpoint in asthma study

Enrollment complete in phase IIa trial of DG-031 for heart attack prevention

Guilford licenses U.S. rights to GPI-1485 to Symphony Neuro Development Company

FDA accepts Genmab IND for phase I/II study of HuMax-CD20 in CLL

Further preclinical data on antirheumatic disease activity of AGIX-4207

New antiviral agents prepared and tested at Bayer

Boehringer Ingelheim presents novel xanthine-based DPP-IV inhibitors

AutoVac vaccines designed for inflammatory and bone diseases

Aventis claims new MMP-13 inhibitors and their use

New Akt kinase inhibitors emerge from Merck R&D

Grelan scientists develop new PDE4 inhibitors for use in respiratory disorders

New antimicrobial agents targeting bacterial aminopeptidase bMAP

Quinazoline-based calcilytic agents newly developed at NPS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...